Table 2.
Allele and genotype frequencies of proinflammatory cytokine gene polymorphisms in common variable immunodeficiency patients in comparison with normal controls.
| Cytokine | Position | Alleles/genotypes | Patients (n = 30) N (%) | Controls (n = 140) N (%) | P-value | OR (95%CI) |
|---|---|---|---|---|---|---|
| TNF-α | −308 | A | 17 (29·3%) | 39 (14·2%) | 0·009 | 2·50 (1·23–5·06) |
| G | 41 (70·7%) | 235 (85·8%) | 0·024 | 0·40 (0·20–0·82) | ||
| AA | 1 (3·4%) | 0 (0) | 0·175 | – | ||
| AG | 15 (51·7%) | 39 (28·5%) | 0·027 | 2·69 (1·10–6·59) | ||
| GG | 13 (44·8%) | 98 (71·5%) | 0·011 | 0·32 (0·13–0·79) | ||
| TNF-α | −238 | A | 7 (10·3%) | 59 (21·5%) | 0·144 | 0·50 (0·20–1·22) |
| G | 51 (89·7%) | 215 (78·5%) | 0·144 | 2·00 (0·82–5·10) | ||
| AA | 0 (0%) | 1 (0·7%) | 0·825 | – | ||
| GA | 7 (20·7%) | 57 (41·6%) | 0·116 | 0·44 (0·16–1·18) | ||
| GG | 22 (79·3%) | 79 (57·7%) | 0·115 | 2·27 (0·84–6·30) | ||
| IL-6 | −174 | C | 33 (56·9%) | 101 (36·3%) | 0·006 | 2·31 (1·25–4·27) |
| G | 25 (43·1%) | 177 (63·7%) | 0·006 | 0·43 (0·23–0·80) | ||
| CC | 5 (17·2%) | 4 (2·9%) | 0·008 | 7·03 (1·49–34–23) | ||
| CG | 23 (79·3%) | 93 (66·9%) | 0·274 | 1·90 (0·67–5·61) | ||
| GG | 1 (3·4%) | 42 (30·2%) | 0·006 | 0·08 (0·00–0·60) | ||
| IL-6 | nt565 | A | 27 (46·6%) | 50 (18·0%) | < 0·001 | 3·97 (2·09–7·56) |
| G | 31 (53·4%) | 228 (82·0%) | < 0·001 | 0·25 (0·13–0·48) | ||
| AA | 2 (6·9%) | 4 (2·9%) | 0·277 | 2·50 (0·30–17·11) | ||
| GA | 23 (79·3%) | 42 (30·2%) | < 0·001 | 8·85 (3·12–26·36) | ||
| GG | 4 (13·8%) | 93 (66·9%) | < 0·001 | 0·08 (0·02–0·26) | ||
| IL-1α | −889 | C | 39 (65·0%) | 186 (68·4%) | 0·723 | 0·86 (0·46–1·61) |
| T | 21 (35·0%) | 86 (31·6%) | 0·723 | 1·16 (0·62–2·18) | ||
| CC | 11 (36·7%) | 62 (45·6%) | 0·492 | 0·69 (0·28–1·67) | ||
| TC | 17 (56·7%) | 62 (45·6%) | 0·369 | 1·56 (0·66–3·73) | ||
| TT | 2 (6·7%) | 12 (8·8%) | 0·518 | 0·74 (0·11–3·80) | ||
| IL-1β | −511 | C | 37 (61·7%) | 154 (55·4%) | 0·456 | 1·30 (0·71–2·39) |
| T | 23 (38·3%) | 124 (44·6%) | 0·456 | 0·77 (0·42–1·42) | ||
| CC | 8 (26·7%) | 36 (25·8%) | 0·808 | 1·24 (0·46–3·26) | ||
| TC | 21 (70·0%) | 82 (59%) | 0·361 | 1·62 (0·65–4·15) | ||
| TT | 1 (3·3%) | 21 (15·2%) | 0·131 | 0·19 (0·01–1·46) | ||
| IL-1β | +3962 | C | 39 (60·0%) | 198 (70·7%) | 0·472 | 0·77 (0·41–1·45) |
| T | 21 (40·0%) | 82 (29·3%) | 0·472 | 1·30 (0·69–2·44) | ||
| CC | 11 (36·7%) | 70 (50%) | 0·260 | 0·58 (0·24–1·40) | ||
| TC | 17 (56·7%) | 58 (41·4%) | 0·186 | 1·85 (0·78–4·42) | ||
| TT | 2 (6·7%) | 12 (8·6%) | 0·536 | 0·76 (0·11–3·92) | ||
| IL-1R | Pst-I 1970 | C | 44 (73·3%) | 174 (62·1%) | 0·136 | 1·68 (0·87–3·27) |
| T | 16 (26·7%) | 106 (44·2%) | 0·136 | 0·60 (0·31–1·15) | ||
| CC | 15 (50·0%) | 54 (38·6%) | 0·341 | 1·59 (0·67–3·78) | ||
| TC | 14 (46·7%) | 66 (47·1%) | 0·876 | 0·98 (0·41–2·32) | ||
| TT | 1 (3·3%) | 20 (14·3%) | 0·129 | 0·21 (0·01–1·56) | ||
| IL-1RA | Mspa-I 11100 | C | 19 (32·8%) | 64 (22·9%) | 0·154 | 1·64 (0·85–3·17) |
| T | 39 (67·2%) | 216 (77·1%) | 0·154 | 0·61 (0·32–1·18) | ||
| CC | 2 (6·9%) | 4 (2·9%) | 0·274 | 2·52 (0·30–17·23) | ||
| CT | 15 (51·7%) | 56 (40%) | 0·338 | 1·61 (0·67–3·86) | ||
| TT | 12 (41·4%) | 80 (57·1%) | 0·178 | 0·53 (0·22–1·28) |
IL, interleukin; TNF, tumour necrosis factor; CI, confidence interval; OR, odds ratio.